ArticleLeukemia2012
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.Leukemia · 2015Trial
- Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.Current oncology reports · 2021Review
- Article
- Molecular biology as a tool for the treatment of cancer.Clinical and experimental medicine · 2018Review
- Article
- Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.Haematologica · 2016Article
- Article
- Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.Oncotarget · 2016Article
- Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform.Current pharmaceutical design · 2016Review
- Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.European journal of cancer (Oxford, England : 1990) · 2014Article
- BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.British journal of cancer · 2013Article
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Blood · 2013Review
- SIAH proteins: critical roles in leukemogenesis.Leukemia · 2013Review
- BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.Leukemia · 2013Article
- Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.Molecular diagnosis & therapy · 2012Article
- Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21818112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.